Semisynthetic human insulin: biologic and immunologic activity in newly treated diabetic subjects during a six-month follow-up.
Biologic and immunogenic activities of semisynthetic human monocomponent insulins were examined in insulin-dependent diabetic patients (group 1). Patients treated with porcine monocomponent (group 2) and conventional (group 3) insulins were studied for control purposes. The patients were examined before the beginning of insulin treatment and for a 6-mo follow-up period. The data collected during the study show that insulin antibody levels were significantly lower in group 1 than in groups 2 and 3. Furthermore, the prevalence of immune complexes assays with the C1q solid phase technique failed to reveal any differences between the three groups. When the conglutinin binding test was used, the prevalence of immune complexes showed a slight but not significant reduction in group 1 and a significant increase in group 3. The metabolic control was similar in the three groups during follow-up and the insulin requirement was lower, but not significantly, in group 1 than in groups 2 and 3. These data suggest that with human monocomponent insulins equivalent glycemic control may be achieved at similar doses than those required with porcine monocomponent insulins. Furthermore, human insulin is the least immunogenic of the present available insulins.
D000328:Adult; D000818:Animals; D000936:Antigen-Antibody Complex / Q000032:analysis; D001667:Binding, Competitive; D003166:Complement Activating Enzymes / Q000378:metabolism; D015922:Complement C1q; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000276:immunology / Q000378:metabolism / Q000592:standards*; D008297:Male; D013552:Swine; D013997:Time Factors
D000936:Antigen-Antibody Complex; D003166:Complement Activating Enzymes; D015922:Complement C1q; D006442:Glycated Hemoglobin; D007328:Insulin